Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most statements provided are non-label informational (pricing, affordability, general lipid knowledge) and some are unsupported or conflict with the label excerpts (e.g., brand vs generic bioequivalence, benzafibrate/bezafibrate inclusion, and several class-wide claims). The label excerpts do not support these assertions as written.
Category Scores
Accurate Statements
Fenofibrate belongs to the fibrates drug class.
Label excerpts provided do not explicitly state 'fibrates drug class,' but the label text repeatedly uses 'fenofibrates' and refers to related fibrate drugs; class naming is consistent with the provided wording.
Fibrates are used to lower cholesterol and triglycerides.
Label excerpts include mechanism and indications related to reducing triglycerides and LDL-C as adjunct to diet (Sections 1 and 12.1), which supports lipid-lowering use generally.
Unsupported Statements
Generic fenofibrate 200 mg is generally more affordable than the brand-name formulation.
Not supported by the provided FDA prescribing information excerpts (Sections 1, 2, 4-8, 12, 14).
Prices of generic fenofibrate 200 mg can range from approximately $10 to over $50 for a 30-day supply without insurance.
Not supported by the provided FDA prescribing information excerpts.
The price of fenofibrate varies depending on pharmacy, insurance coverage, and whether a generic or brand-name version is purchased.
Not supported by the provided FDA prescribing information excerpts.
Insurance plans affect out-of-pocket expenses for fenofibrate via copays and deductibles.
Not supported by the provided FDA prescribing information excerpts.
Factors influencing the cost of fenofibrate include the manufacturer, dosage strength, quantity of pills in a prescription, and retail markup at individual pharmacies.
Not supported by the provided FDA prescribing information excerpts.
Fenofibrate contains the same active ingredient in both brand-name and generic formulations.
Not supported by the provided FDA label excerpts.
Brand-name and generic fenofibrate are required to demonstrate bioequivalence by regulatory agencies.
Not supported by the provided FDA label excerpts.
There can be minor differences in inactive ingredients between brand-name and generic fenofibrate.
Not supported by the provided FDA label excerpts.
Differences in inactive ingredients between brand-name and generic fenofibrate typically do not affect efficacy or safety.
Not supported by the provided FDA label excerpts.
Generics are usually considerably less expensive than brand-name fenofibrate.
Not supported by the provided FDA label excerpts.
Other medications in the fibrates class include gemfibrozil and bezafibrate.
The label excerpt explicitly references gemfibrozil and other fibrates such as clofibrate (Section 5.1), but bezafibrate is not mentioned in the provided label excerpts.
Statins such as atorvastatin and rosuvastatin are commonly prescribed for lipid management.
Not supported by the provided FDA label excerpts.
Statins may be considered alongside or as alternatives to fibrates depending on a patient's lipid profile and risk factors.
The label excerpts discuss avoiding concomitant use of statins unless benefit outweighs increased risk (Section 5.3) but do not support a broad 'may be considered alongside or as alternatives' statement as written.
Contradictions
Low
AI Statement
Brand-name and generic fenofibrate are required to demonstrate bioequivalence by regulatory agencies.
Label Reference
Unsupported by provided Antara prescribing information excerpts (no bioequivalence language present in Sections provided).
Low
AI Statement
Other medications in the fibrates class include gemfibrozil and bezafibrate.
Label Reference
Section 5.1 references similarities between fenofibrates and includes gemfibrozil and clofibrate, but bezafibrate is not included in provided excerpts.
Important Omissions
If the AI response intended to discuss Antara-specific use, it omitted key label limitations and safety statements relevant to lipid-lowering therapy (e.g., indications with TG ≥500 mg/dL or primary hyperlipidemia when LDL-C therapy not possible; limitations on pancreatitis risk determination and lack of coronary heart disease morbidity/mortality benefit in type 2 diabetes; major contraindications such as severe renal impairment and active liver disease; and warnings such as hepatotoxicity, myopathy/rhabdomyolysis, cholelithiasis, pancreatitis, and bleeding risk with coumarin anticoagulants).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements are not label-supported and could mislead about efficacy/safety applicability (e.g., broad claims about statin-fibrate use and generic substitution equivalence). No explicit contraindication-violating dosing claim was made, but omission of Antara-specific boxed/major warning context is material.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple statements are unrelated to the FDA-approved prescribing information excerpts (pricing) and several clinical equivalence/classification claims are unsupported or not reflected in the provided label text.
Suggested Improvement
Limit content to what is supported by the Antara label excerpts (indications, dosing/administration, contraindications, and labeled warnings/precautions and drug interaction cautions such as with statins, anticoagulants, and bile-acid resins). Remove non-label pricing/equivalence assertions and avoid naming additional drugs (e.g., bezafibrate) unless present in the provided label.